BioCentury | Feb 5, 2019
Distillery Therapeutics

Cancer

...no treatment. Next steps could include testing the USP7 inhibitors in mouse models of HCC. Hybrigenics...
BioCentury | Nov 2, 2017
Targets & Mechanisms

Golden State of DUBs

...Mission Therapeutics Ltd. USP7 inhibitors USP7 Cancer Preclinical Progenra Inc. USP7 inhibitor USP7 Cancer Preclinical Hybrigenics...
BioCentury | Sep 19, 2016
Clinical News

Inecalcitol: Phase II started

...chemotherapy. Hybrigenics has exclusive, worldwide rights to inecalcitol from Merck (see BioCentury, Feb. 13, 2006). Hybrigenics...
BioCentury | Jul 13, 2015
Finance

Tiers, some fears

...Inc. (NASDAQ:CERU) 4/7/15 $40.30 $162.6 $125.5 -23% Dyax Corp. (NASDAQ:DYAX) 4/7/15 $229.77 $3,923.1 $3,860.4 -2% Hybrigenics...
BioCentury | Jun 8, 2015
Company News

PicoSeq, Hybrigenics, Ecole Normale Superieure, Bpifrance deal

...EPIGENETIX2, was selected for funding in the second phase of the French Worldwide Innovation Challenge. Hybrigenics...
...of the French Worldwide Innovation Challenge. PicoSeq will be responsible for SIMDEQ’s global commercialization. PicoSeq, Hybrigenics...
...to provide further details, and Bpifrance could not be reached. PicoSeq S.A.S. , Paris, France Hybrigenics...
BioCentury | Feb 2, 2015
Company News

Hybrigenics, Servier deal

...by one year its 2011 deal with Servier to identify compounds against deubiquitinating enzyme targets. Hybrigenics...
...€920,000 ($1 million) for the extension (see BioCentury, Oct. 17, 2011 & Feb. 3, 2014). Hybrigenics...
BioCentury | Nov 3, 2014
Financial News

Hybrigenics completes private placement

Hybrigenics S.A. (Euronext:ALHYG), Paris, France Business: Cancer, Proteomics, Supply/Service Date completed: 2014-10-22 Type: Private placement Raised: EUR4.6 million ($5.9 million) Shares: 3.5 million Price: EUR1.32 Shares after offering: 29.4 million Investor: Crede Capital Group WIR...
BioCentury | Oct 9, 2014
Distillery Therapeutics

Indication: Cancer

...a vitamin D analog, in Phase IIa testing to treat secondary hyperparathyroidism. Merck KGaA and Hybrigenics...
BioCentury | May 26, 2014
Clinical News

Inecalcitol regulatory update

...FDA granted Orphan Drug designation to inecalcitol from Hybrigenics to treat chronic lymphocytic leukemia (CLL). The...
...CLL. Hybrigenics has exclusive, worldwide rights to inecalcitol from Merck (see BioCentury, Feb. 13, 2006). Hybrigenics...
BioCentury | Apr 7, 2014
Financial News

Hybrigenics completes private placement

...after offering: 25.9 million Investors: Pradeyrol Developpement; existing investors; new investors Note: Allegra Finance advised Hybrigenics. WIR...
Items per page:
1 - 10 of 128
BioCentury | Feb 5, 2019
Distillery Therapeutics

Cancer

...no treatment. Next steps could include testing the USP7 inhibitors in mouse models of HCC. Hybrigenics...
BioCentury | Nov 2, 2017
Targets & Mechanisms

Golden State of DUBs

...Mission Therapeutics Ltd. USP7 inhibitors USP7 Cancer Preclinical Progenra Inc. USP7 inhibitor USP7 Cancer Preclinical Hybrigenics...
BioCentury | Sep 19, 2016
Clinical News

Inecalcitol: Phase II started

...chemotherapy. Hybrigenics has exclusive, worldwide rights to inecalcitol from Merck (see BioCentury, Feb. 13, 2006). Hybrigenics...
BioCentury | Jul 13, 2015
Finance

Tiers, some fears

...Inc. (NASDAQ:CERU) 4/7/15 $40.30 $162.6 $125.5 -23% Dyax Corp. (NASDAQ:DYAX) 4/7/15 $229.77 $3,923.1 $3,860.4 -2% Hybrigenics...
BioCentury | Jun 8, 2015
Company News

PicoSeq, Hybrigenics, Ecole Normale Superieure, Bpifrance deal

...EPIGENETIX2, was selected for funding in the second phase of the French Worldwide Innovation Challenge. Hybrigenics...
...of the French Worldwide Innovation Challenge. PicoSeq will be responsible for SIMDEQ’s global commercialization. PicoSeq, Hybrigenics...
...to provide further details, and Bpifrance could not be reached. PicoSeq S.A.S. , Paris, France Hybrigenics...
BioCentury | Feb 2, 2015
Company News

Hybrigenics, Servier deal

...by one year its 2011 deal with Servier to identify compounds against deubiquitinating enzyme targets. Hybrigenics...
...€920,000 ($1 million) for the extension (see BioCentury, Oct. 17, 2011 & Feb. 3, 2014). Hybrigenics...
BioCentury | Nov 3, 2014
Financial News

Hybrigenics completes private placement

Hybrigenics S.A. (Euronext:ALHYG), Paris, France Business: Cancer, Proteomics, Supply/Service Date completed: 2014-10-22 Type: Private placement Raised: EUR4.6 million ($5.9 million) Shares: 3.5 million Price: EUR1.32 Shares after offering: 29.4 million Investor: Crede Capital Group WIR...
BioCentury | Oct 9, 2014
Distillery Therapeutics

Indication: Cancer

...a vitamin D analog, in Phase IIa testing to treat secondary hyperparathyroidism. Merck KGaA and Hybrigenics...
BioCentury | May 26, 2014
Clinical News

Inecalcitol regulatory update

...FDA granted Orphan Drug designation to inecalcitol from Hybrigenics to treat chronic lymphocytic leukemia (CLL). The...
...CLL. Hybrigenics has exclusive, worldwide rights to inecalcitol from Merck (see BioCentury, Feb. 13, 2006). Hybrigenics...
BioCentury | Apr 7, 2014
Financial News

Hybrigenics completes private placement

...after offering: 25.9 million Investors: Pradeyrol Developpement; existing investors; new investors Note: Allegra Finance advised Hybrigenics. WIR...
Items per page:
1 - 10 of 128